HEP DART 2019: Frontiers in Drug Development for Hepatology
HEP DART 2019: Frontiers in Drug Development for Hepatology
批准号:
9914390
负责人:
Charles M Rice
金额:
$0.85万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2019
资助国家:
美国
项目状态:
已结题
起止时间:
2019-11-20 至 2020-10-31
关键词:
AccreditationAddressAdolescentAreaAtmosphereAwardBiologyCategoriesChemistryClinicalClinical ResearchCommunitiesDevelopmentDiseaseDisease OutcomeDoctor of PhilosophyEducational workshopEnsureEpidemiologyEventFacultyFibrosisFutureGrantGuidelinesHIVHealth PersonnelHealth ProfessionalHepatitisHepatitis B TherapyHepatitis B VirusHepatitis C virusHepatologyInfectionInternationalKnowledgeLearningLiver diseasesMalignant NeoplasmsMedicalMinorityNursesOralPathogenesisPediatricsPharmacologyPhysician AssistantsPhysiciansPopulationPostdoctoral FellowPrimary carcinoma of the liver cellsProcessRegimenResearch PersonnelRoleScholarshipScientistTherapeuticTrainingTravelTreatment ProtocolsTreatment outcomeUniversitiesVaccinationVaccinesViral hepatitisVirusVirus DiseasesWomanchronic liver diseaseclinical developmentco-infectioncontinuing medical educationcostdrug developmentfrontiergraduate studentimprovedinterestliver infectionnonalcoholic steatohepatitisnovelnovel markernovel therapeuticsposterssymposiumtherapeutic developmenttherapeutic vaccinetherapy developmentvaccine developmentvaccinology
中文摘要
摘要/项目概述:
英文摘要
Abstract/ Project summary:
HEP DART: Frontiers in Drug Development for Hepatology is an independent biennial conference
attracting at least 250 attendees for the past 24 years. HEP DART is open to anyone interested in
therapies for viral hepatitis and chronic liver disease. The content of this conference was developed to
interest primarily scientists and clinical researchers with a focus on drug development and
vaccinology. The aim of HEP DART 2019 is to assemble clinicians, researchers, basic scientists, nurses
and physician assistants together to advance our knowledge of the ongoing drug development
processes in the treatment of viral hepatitis (HBV, HCV, HDV, HAV and HEV), non‐‐‐alcoholic
steatohepatitis (NASH) and hepatocellular carcinoma (HCC). HEP DART will uniquely blend the
areas of biology, chemistry, pharmacology and clinical research to provide the scientific community
with an increased understanding of the current and future challenges in therapeutics for liver infection,
disease and cancer. OBJECTIVES: (1) Highlight advances in drug development against viral hepatitis
such as HBV, HCV, and HDV. (2) Describe the latest developments in HBV curative strategies. (3)
Highlight advances in drug development against NASH, fibrosis and HCC. (4) Describe novel
biomarkers for viral hepatitis, liver disease, and treatment outcomes. (5) Review current treatment and
vaccination guidelines for viral hepatitis; describe advancements in improved treatment regimens. (6)
Understand the consequences of HBV infection and NASH in pediatrics and adolescent populations. (7)
Assess the role of vaccines and therapeutic vaccines in future therapies for viral hepatitis, NASH, and
co‐‐‐infections with HIV. (8) Understand the epidemiology and pathogenesis of HDV, HAV and HEV.
METHODS: HEP DART 2019 comprises four days of scientific presentations, delivered in both oral
and poster presentations formats via non‐‐‐concurrent sessions. Emory University, Office of
Continuing Medical Education designates HEP DART for a maximum 24 category 1 credits toward the
AMA Physician’s Recognition Award. HEP DART provides a relaxed and scientifically stimulating
atmosphere for both PhDs and MDs to network and learn together. Support is requested to help defray
costs of scholarships and travel grants for young investigators, women, visible minorities and other
under‐‐‐represented delegates.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Employing viruses to unravel the functional significance of the m5C epitranscriptome
-
批准号:10638533
-
项目类别:
-
资助金额:$66.0万
-
财政年份:2023
-
负责人:Charles M Rice
-
依托单位:
Elucidating the mechanism by which ADAR1 prevents autoimmunity against self RNA
-
批准号:10667182
-
项目类别:
-
资助金额:$25.43万
-
财政年份:2023
-
负责人:Charles M Rice
-
依托单位:
Tracking SARS-CoV-2 one molecule at a time: Spatiotemporal investigation of coronavirus replication dynamics and host response in single cells in vitro and in vivo
-
批准号:10446423
-
项目类别:
-
资助金额:$63.76万
-
财政年份:2022
-
负责人:Charles M Rice
-
依托单位:
A clear view of encephalitis: a single cell approach to determine the basis of flaviviral pathogenesis in the central nervous system
-
批准号:10553697
-
项目类别:
-
资助金额:$62.82万
-
财政年份:2022
-
负责人:Charles M Rice
-
依托单位:
Tracking SARS-CoV-2 one molecule at a time: Spatiotemporal investigation of coronavirus replication dynamics and host response in single cells in vitro and in vivo
-
批准号:10570297
-
项目类别:
-
资助金额:$61.93万
-
财政年份:2022
-
负责人:Charles M Rice
-
依托单位:
Scientific Core: BSL3 Virology and Animal Models
-
批准号:10327991
-
项目类别:
-
资助金额:$145.45万
-
财政年份:2022
-
负责人:Charles M Rice
-
依托单位:
Scientific Core: BSL3 Virology and Animal Models
-
批准号:10841239
-
项目类别:
-
资助金额:$98.31万
-
财政年份:2022
-
负责人:Charles M Rice
-
依托单位:
A clear view of encephalitis: a single cell approach to determine the basis of flaviviral pathogenesis in the central nervous system
-
批准号:10446620
-
项目类别:
-
资助金额:$68.19万
-
财政年份:2022
-
负责人:Charles M Rice
-
依托单位:
Virology Core
-
批准号:10513915
-
项目类别:
-
资助金额:$528.97万
-
财政年份:2022
-
负责人:Charles M Rice
-
依托单位:
TMEM41B: a pan-flavivirus and pan-coronavirus host factor with antiviral potential
-
批准号:10587597
-
项目类别:
-
资助金额:$46.09万
-
财政年份:2022
-
负责人:Charles M Rice
-
依托单位:
TMEM41B: a pan-flavivirus and pan-coronavirus host factor with antiviral potential
-
批准号:10707260
-
项目类别:
-
资助金额:$61.01万
-
财政年份:2022
-
负责人:Charles M Rice
-
依托单位:
A renewable and genetically tractable human stem cell-derived multicellular platform for the study of fibrotic liver diseases
-
批准号:10576892
-
项目类别:
-
资助金额:$49.43万
-
财政年份:2021
-
负责人:Charles M Rice
-
依托单位:
A renewable and genetically tractable human stem cell-derived multicellular platform for the study of fibrotic liver diseases
-
批准号:10360541
-
项目类别:
-
资助金额:$49.43万
-
财政年份:2021
-
负责人:Charles M Rice
-
依托单位:
A renewable and genetically tractable human stem cell-derived multicellular platform for the study of fibrotic liver diseases
-
批准号:10211567
-
项目类别:
-
资助金额:$50.99万
-
财政年份:2021
-
负责人:Charles M Rice
-
依托单位:
Defining therapeutic drug targets for SARS-CoV-2-specific and pan-coronavirus inhibition
-
批准号:10238377
-
项目类别:
-
资助金额:$48.35万
-
财政年份:2021
-
负责人:Charles M Rice
-
依托单位:
Launching HBV with RNA to assess antiviral resistance and explore fundamental aspects of virus-host biology
-
批准号:10555333
-
项目类别:
-
资助金额:$61.11万
-
财政年份:2020
-
负责人:Charles M Rice
-
依托单位:
Identification of host factors required by the tick-borne Powassan virus
-
批准号:10154884
-
项目类别:
-
资助金额:$25.43万
-
财政年份:2020
-
负责人:Charles M Rice
-
依托单位:
Identification of host factors required by the tick-borne Powassan virus
-
批准号:10307148
-
项目类别:
-
资助金额:$21.19万
-
财政年份:2020
-
负责人:Charles M Rice
-
依托单位:
In search of an HBV cure: novel model systems and targets
-
批准号:10400212
-
项目类别:
-
资助金额:$59.43万
-
财政年份:2019
-
负责人:Charles M Rice
-
依托单位:
In search of an HBV cure: novel model systems and targets
-
批准号:10633080
-
项目类别:
-
资助金额:$59.43万
-
财政年份:2019
-
负责人:Charles M Rice
-
依托单位:
海外基金